Gilead Sciences Inc. (NASDAQ:GILD) belongs to Healthcare sector. Its net profit margin is 51.70% and weekly performance is 1.94%. On last trading day company shares ended up $117.36. Gilead Sciences Inc. (NASDAQ:GILD) distance from 50-day simple moving average (SMA50) is 3.83%. On 3 July, Gilead Sciences, Inc. (NASDAQ:GILD) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Harvoni® (ledipasvir 90 mg/sofosbuvir 400 mg), the first once-daily single tablet regimen for the treatment of chronic hepatitis C genotype 1 infection in adults. Harvoni combines the NS5A inhibitor ledipasvir with the nucleotide analog polymerase inhibitor sofosbuvir, approved by the MHLW under the trade name Sovaldi® in March 2015.
Theravance Inc. (NASDAQ:THRX) shares advanced 2.54% in last trading session and ended the day at $16.96. THRX return on assets is -20.60%. Theravance Inc. (NASDAQ:THRX) quarterly performance is -4.02%. Theravance, Inc. (NASDAQ:THRX) announced the appointment of Michael E. Faerm as Senior Vice President and Chief Business Officer. Mr. Faerm reports directly to Michael W. Aguiar, Chief Executive Officer, and will lead Theravance’s growth strategy and corporate development initiatives beyond the company’s existing respiratory portfolio of RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R).
On 14 July, Bio-Techne Corp. (NASDAQ:TECH) shares advanced 1.99% and was closed at $102.65. TECH EPS growth in last 5 year was 1.50%. Bio-Techne Corp. (NASDAQ:TECH) year to date (YTD) performance is 11.85%. Bio-Techne Corporation (NASDAQ:TECH) announced that management will host a conference call on Thursday, August 6, 2015, at 8:00 a.m. CDT to review fourth quarter fiscal 2015 financial results.
Grifols, S.A. (NASDAQ:GRFS) ended the last trading day at $32.30. Company weekly volatility is calculated as 1.45%. Grifols, S.A. (NASDAQ:GRFS) showed a weekly performance of 4.90%. Grifols SA, Barcelona (NASDAQ:GRFS) has received a “BB+” credit rating from analysts at Morningstar. The research firm’s “BB+” rating suggests that the company is an above-average default risk. They also gave their stock a four star rating.
Amgen Inc. (NASDAQ:AMGN) shares advanced 2.29% in last trading session and ended the day at $159.32. AMGN Gross Margin is 80.70% and its return on assets is 8.20%. Amgen Inc. (NASDAQ:AMGN) quarterly performance is -1.52%.